An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells

Gene Therapy

Volumn 14, Issue 16, 2007, Pages 1218-1225

  Fu, X ^a,b   Tao, L ^a,b   Zhang, X ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS; PROTEIN ICP10; PROTEIN KINASE; RAS PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ESOPHAGUS TUMOR; FEMALE; GENE DELETION; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; LETHALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BYSTANDER EFFECT; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; FEMALE; GENE DELETION; HUMANS; IN SITU NICK-END LABELING; INJECTIONS, INTRALESIONAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; RIBONUCLEOTIDE REDUCTASES; VIRUS REPLICATION;

HUMAN HERPESVIRUS 2; MUS; SIMPLEXVIRUS;

EID: 34547734438     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302971     Document Type: Article

References (34)

1. Varghese S, Rabki SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Therapy 2002; 9: 967-978.
2. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a geneticaUy engineered virus mutant. Science 1991; 252: 854-856.
3. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994; 54: 3963-3966.
4. Boviatsis EJ, Scharf JM, Chase M, Harrington K, Kowall NW, Breakefield XO et al. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Therapy 1994; 1: 323-331.
5. Pyles RB, Warnick RE, Chalk CL, Szanti BE, Parysek LM. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther 1997; 8: 533-544.
6. Chou J, Roizman B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma ceUs from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci USA 1992; 89: 3266-3270.
7. Chou J, Kein ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma, 34.5, a gene non-essential for growth in culture. Science 1990; 250: 1262-1266.
8. Bolovan CA, Sawtell NM, Thompson RL. ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J Virol 1994; 68: 48-55.
9. Chou J, Poon AP, Johnson J, Roizman B. Differential response of human cells to deletions and stop codons in the gamma(1)34.5 gene of herpes simplex virus. J Virol 1994, 68: 8304-8311.
10. Chambers R, Gillespie GY, Soroceanu L, Andreansky S, Chatterjee S, Chou J et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA 1995; 92: 1411-1415.
11. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY et al. Evaluation of geneticaUy engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 1997; 57: 1502-1509.
12. Fu X, Tao L, Cai R, Prigge J, Zhang X. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol Ther 2006; 13: 882-890.
13. Smith CC, Nelson J, Aurelian L, Gober M, Goswami BB. Ras- GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth. J Virol 2000; 74: 10417-10429.
14. Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001; 3: 745-750.
15. Smith CC, Peng T, Kulka M, Aurelian L. The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth. J Virol 1998; 72: 9131-9141.
16. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
17. Fu X, Tao L, Li M, Fisher WE, Zhang X. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes sunplex virus. Clin Cancer Res 2006; 12: 3152-3157.
18. Koyama AH, Fukumori T, Fujita M, Irie H, Adachi A. Physiological significance of apoptosis in animal virus infectiom Microbes Infect 2000; 2, 1111-1117.
19. Everett H, McFadden G. Apoptosis: An innate immune response to virus infection. Trends Microbiol 1999; 7: 160-165.
20. Goodkin ML, Morton ER, Blaho JA. Herpes simplex virus infection and apoptosis. Int Rev Immunol 2004; 23: 141-172.
21. Perkins D, Pereira EF, Gober M, Yarowsky PJ, Aurelian L. The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) blocks apoptosis in hippocampal neurons, involving activation of the MEK/MAPK survival pathway. J Virol 2002, 76: 1435-1449.
22. Koyama AH, Adachi A. Induction of apoptosis by herpes simplex virus type 1. J Gen Virol 1997; 78 (Part 11): 2909-2912.
23. Aubert M, O'Toole J, Blaho JA. Induction and prevention of apoptosis in human HEp-2 cells by herpes simplex virus type 1. J Virol 1999; 73: 10359-10370.
24. Nimmanapalli R, Bhalla K. Targets in apoptosis signaling: Promise of selective anticancer therapy. Methods Mol Biol 2003; 223: 465-483.
25. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci USA 2005; 102: 14034-14039.
26. Stanziale SF, Petrowsky H, Adusumilli PS, Ben-Porat L, Gonen M, Fong Y. Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: A potential target to increase anticancer activity. Clin Cancer Res 2004; 10: 3225-3232.
27. Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res. 2002; 62: 2306-2312.
28. Nakamori M, Fu X, Rousseau R, Chen SY, Zhang X. Destruction of nonimmunogenic in mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther 2004; 9: 658-665.
29. Ebert O, Shinozaki K, Kournioti C, Park MS, Garcia-Sastre A, Woo SL. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 2004; 64 3265-3270.
30. Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002; 21: 8541-8546.
31. McCormick F. New-age drug meets resistance. Nature 2001; 412 281-282.
32. Li W, Ding F, Zhang L, Liu Z, Wu Y, Luo A et al. Overexpression of stefin A in human esophageal squamous cell carcinoma cells inhibits tumor cell growth, angiogenesis, invasion, and metastasis. Clin Cancer Res 2005; 11: 8753-8762.
33. Fu X, Tao, L, Jin A, Vile P, Brenner M, Zhang X. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus provides potent synergistic anti-tumor effect. Mol Ther 2003; 7 748-754.
34. Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast RCJ et al. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane-fusion mechanisms. Clin Cancer Res 2003; 9: 2727-2733.